title: Targeting oncogenic miR-335 inhibits growth and invasion of malignant astrocytoma cells.
abstract: BACKGROUND
  Astrocytomas are the most common and aggressive brain tumors characterized by their highly invasive growth. Gain of chromosome 7 with a hot spot at 7q32 appears to be the most prominent aberration in astrocytoma. Previously reports have shown that microRNA-335 (miR-335) resided on chromosome 7q32 is deregulated in many cancers; however, the biological function of miR-335 in astrocytoma has yet to be elucidated.
  
  
  RESULTS
  We report that miR-335 acts as a tumor promoter in conferring tumorigenic features such as growth and invasion on malignant astrocytoma. The miR-335 level is highly elevated in C6 astrocytoma cells and human malignant astrocytomas. Ectopic expression of miR-335 in C6 cells dramatically enhances cell viability, colony-forming ability and invasiveness. Conversely, delivery of antagonist specific for miR-335 (antagomir-335) to C6 cells results in growth arrest, cell apoptosis, invasion repression and marked regression of astrocytoma xenografts. Further investigation reveals that miR-335 targets disheveled-associated activator of morphogenesis 1(Daam1) at posttranscriptional level. Moreover, silencing of endogenous Daam1 (siDaam1) could mimic the oncogenic effects of miR-335 and reverse the growth arrest, proapoptotic and invasion repression effects induced by antagomir-335. Notably, the oncogenic effects of miR-335 and siDAAM1 together with anti-tumor effects of antagomir-335 are also confirmed in human astrocytoma U87-MG cells.
  
  
  CONCLUSIONS
  These findings suggest an oncogenic role of miR-335 and shed new lights on the therapy of malignant astrocytomas by targeting miR-335.
authors: Department of Pharmacology, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou, China.
authors: Minfeng
authors: M
authors: Shu
authors: Xiaoke
authors: X
authors: Zheng
authors: Sihan
authors: S
authors: Wu
authors: Huimin
authors: H
authors: Lu
authors: Tiandong
authors: T
authors: Leng
authors: Wenbo
authors: W
authors: Zhu
authors: Yuehan
authors: Y
authors: Zhou
authors: Yanqiu
authors: Y
authors: Ou
authors: Xi
authors: X
authors: Lin
authors: Yuan
authors: Y
authors: Lin
authors: Dong
authors: D
authors: Xu
authors: Yuxi
authors: Y
authors: Zhou
authors: Guangmei
authors: G
authors: Yan
references: BMC Med Genomics. 2008 Aug 13;1:37
references: 18700954
references: Cell. 2007 Dec 28;131(7):1273-86
references: 18155131
references: Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2812-7
references: 19196975
references: Cell. 2009 Feb 20;136(4):586-91
references: 19239879
references: N Engl J Med. 2001 Jan 11;344(2):114-23
references: 11150363
references: Cancer Res. 2008 Apr 15;68(8):2745-54
references: 18417445
references: Mol Cell Biol. 2002 Oct;22(20):7015-23
references: 12242282
references: Pathol Res Pract. 2010 Oct 15;206(10):663-8
references: 20570053
references: Cancer Res. 2005 Oct 1;65(19):8792-800
references: 16204049
references: N Engl J Med. 2005 Mar 10;352(10):987-96
references: 15758009
references: J Neurooncol. 1994;19(3):259-68
references: 7807177
references: Cell Cycle. 2008 Aug 15;7(16):2485-92
references: 18719380
references: Proc Natl Acad Sci U S A. 2010 Apr 13;107(15):6906-11
references: 20351293
references: Nature. 2008 Dec 18;456(7224):980-4
references: 19043405
references: Neurochem Int. 2005 Nov;47(6):430-41
references: 16087277
references: Development. 2011 Jan;138(2):303-15
references: 21177343
references: Fertil Steril. 2008 Jun;89(6):1771-6
references: 17765232
references: BMC Cancer. 2010 Sep 21;10:502
references: 20858276
references: Dev Biol. 2009 Jun 1;330(1):44-53
references: 19306866
references: Am J Pathol. 2005 Jun;166(6):1841-50
references: 15920168
references: Arch Immunol Ther Exp (Warsz). 2007 Mar-Apr;55(2):61-75
references: 17347801
references: PLoS One. 2008 May 21;3(5):e2236
references: 18493594
references: Neuromolecular Med. 2009;11(3):208-22
references: 19731102
references: Nat Rev Cancer. 2006 Apr;6(4):259-69
references: 16557279
references: Cell Death Differ. 2011 Jun;18(6):985-95
references: 21164520
references: Cancer Res. 2010 Jul 15;70(14):6015-25
references: 20610624
references: Oncogene. 2008 Apr 3;27(15):2128-36
references: 17968323
references: Cell. 2006 Jun 16;125(6):1111-24
references: 16777601
references: J Dig Dis. 2010 Feb;11(1):50-4
references: 20132431
references: Cancer Res. 2009 Feb 1;69(3):1135-42
references: 19155302
references: Proc Natl Acad Sci U S A. 2009 Feb 10;106(6):1814-9
references: 19188590
references: Nature. 2005 Jun 9;435(7043):834-8
references: 15944708
references: Cancer Res. 2010 Sep 1;70(17):6925-33
references: 20713524
references: Mol Oncol. 2011 Jun;5(3):265-72
references: 21470923
references: Cancer Res. 2009 Jul 15;69(14):5776-83
references: 19584273
references: Exp Cell Res. 2002 Aug 1;278(1):45-52
references: 12126956
references: JAMA. 2008 Jan 30;299(4):425-36
references: 18230780
references: PLoS One. 2010 Sep 29;5(9):
references: 20927366
references: J Clin Oncol. 2005 Apr 1;23(10):2411-22
references: 15800333
references: Science. 2007 Dec 21;318(5858):1931-4
references: 18048652
references: Oncogene. 2006 Oct 9;25(46):6202-10
references: 17028600
references: Oncogene. 2008 Dec;27 Suppl 2:S52-7
references: 19956180
references: Cancer Cell. 2002 Oct;2(4):323-34
references: 12398896
references: Nature. 2008 Jan 10;451(7175):147-52
references: 18185580
references: Nat Med. 2007 May;13(5):613-8
references: 17468766
references: Mol Cell Biol. 2008 Sep;28(17):5369-80
references: 18591254
references: Genes Dev. 2011 Feb 1;25(3):226-31
references: 21289068
references: Cancer Res. 2009 Jun 1;69(11):4851-60
references: 19487295
references: Oncogene. 2010 Mar 18;29(11):1580-7
references: 19966857
references: Lab Invest. 2010 Sep;90(9):1285-94
references: 20548289